
Gilteritinib and Prior Midostaurin/Sorafenib Aids Clinical Response in Patients with FLT3-Mutated AML
Gilteritinib monotherapy reacts favorably and led to higher rates of composite complete remissions in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia who received prior midostaurin or sorafenib.


















